6533b825fe1ef96bd12829f9
RESEARCH PRODUCT
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry
Andrea ChiricozziMarina TalamontiClara De SimoneMarco GalluzzoNiccolò GoriGabriella FabbrociniAngelo Valerio MarzanoGiampiero GirolomoniAnnamaria OffidaniMaria Teresa RossiLuca BianchiAntonio CristaudoMaria Teresa FierroLuca StingeniGiovanni PellacaniGiuseppe ArgenzianoAnnalisa PatriziPaolo PigattoMarco RomanelliPaola SavoiaPietro RubegniCaterina FotiNicola MilanesiAnna Belloni FortinaMaria Rita BongiornoTeresa GriecoSergio Di NuzzoMaria Concetta FargnoliAndrea CarugnoAlberico MotoleseFranco RongiolettiPaolo AmerioRiccardo BalestriConcetta PotenzaGiuseppe MicaliCataldo PatrunoIris ZalaudekMaurizio LombardoClaudio FelicianiLucia Di NardoFabrizio GuarneriKetty PerisGiacomo CaldarolaDionisio SilvaggioAnnunziata DattolaMaddalena NapolitanoSilvia Mariel FerrucciGiacomo Dal BelloTommaso BianchelliChiara RovatiFlavia PigliacelliMichela OrtoncelliKatharina HanselGiulia CalabreseCamilla LoiMichela IannoneFederica VeronesePaolo RomitaGreta TronconiFrancesca CaroppoGiovanna TilottaAlvise SernicolaMaria EspositoFrancesca RaponiGiulio GualdiGiulia RechMaria Letizia MusumeciSteven Paul NisticòAlessio CampitielloLaura BonzanoViviana Pirassubject
Registrie0301 basic medicineDermatitisSystemic therapy0302 clinical medicinePandemicImmunology and AllergyMedicineRegistriesatopic dermatitis; COVID; SARS‐ CoVCOVIDtreatmentatopic dermatitisatopic dermatitis; COVID; SARS-CoVSARS-CoVAtopic dermatitisDupilumabSARS‐ CoVItalyOriginal ArticleSettore MED/35 - MALATTIE CUTANEE E VENEREEHumanatopic dermatitiAdultmedicine.medical_specialtyTeledermatologyCOVID; SARS‐CoV; atopic dermatitis treatmentCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCOVID; SARS‐CoV; atopic dermatitis; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis AtopicAtopicDermatitis Atopic03 medical and health sciencesSettore MED/35Disease severityInternal medicineatopic dermatitis treatmentHumansPandemicsPandemicbusiness.industrySARS-CoV-2SARS‐CoVCOVID-19medicine.disease030104 developmental biology030228 respiratory systemCommunicable Disease Controlatopic dermatitis; COVID; SARS-CoV; Adult; Communicable Disease Control; Humans; Italy; Pandemics; Registries; SARS-CoV-2; COVID-19; Dermatitis Atopicatopic dermatitis COVID SARS-CoVbusinessdescription
Abstract Background Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID‐19) pandemic. Methods A national registry, named DA‐COVID‐19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID‐19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID‐19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician‐ and patient‐reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS‐CoV‐2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS‐CoV‐2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID‐related death occurred. Conclusions Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab‐treated patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-03-09 |